<DOC>
	<DOCNO>NCT01016769</DOCNO>
	<brief_summary>The purpose study find good bad effect occur temsirolimus added standard chemotherapy carboplatin paclitaxel .</brief_summary>
	<brief_title>Temsirolimus + Weekly Paclitaxel + Carboplatin Recurrent Metastatic Head Neck Squamous Cell Cancer ( HNSCC )</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients must microscopically confirm head neck squamous cell carcinoma ( HNSCC ) , recurrent and/or metastatic . Confirmation HNSCC may obtain primary site metastatic disease . Patients must least 18 year age . Karnofsky Performance status must ≥ 70 % . Disease must measurable RECIST criterion . At least 6 week must elapse previous radiation therapy . Patient must recover acute toxic effect treatment prior study enrollment . Adequate organ function , follow : Adequate bone marrow reserve : absolute neutrophil count ( ANC ) ≥ 1.5 X 109/L , platelet ≥ 100 X 109/L , hemoglobin ≥ 9 g/dL . Hepatic : total bilirubin within normal limit ( ≤ 1.0 mg/dL ) ; alkaline phosphatase ( AP ) , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 1.5 X ULN ( upper limit normal ) Renal : Serum creatinine ≤ 1.3 mg/dL . Patients serum creatinine &gt; 1.3 mg/dL may eligible creatinine clearance ( CrCl ) ≥ 45 mL/min base standard Cockroft Gault formula . Patients childbearing potential must negative serum pregnancy test within 14 day treatment . Patients must agree use reliable method birth control 3 month follow last dose study drug . Patients must sign informed consent document . Previous exposure temsirolimus mTOR inhibitor More 2 prior cytotoxic regimens recurrent/metastatic disease set History brain metastasis Patients require concomitant medication metabolize hepatic CYP3A4 , due potential drugdrug interaction temsirolimus Patients know active interstitial pneumonitis Active infection serious underlie medical condition would impair patient 's ability receive protocol treatment . Women pregnant lactate Other active malignancy , indolent malignancy investigator determines unlikely interfere treatment safety analysis Diagnosis Nasopharyngeal cancer exclude . Patients multifocal peripheral sensory alteration paresthesias ( include tingle ) interfere function , per patient report ( example : activity daily live ) Therapeutic anticoagulation Coumadin ( warfarin ) Hypertriglyceridemia ≥ grade 2 ( CTCAE version 3.0 ) . Impaired lung function : O2 saturation 88 % less rest room air Pulse Oximetry . If O2 saturation ≤ 88 % rest , pulmonary function test ( PFTs ) order confirm normal pulmonary function eligibility .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Paclitaxel</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Head Neck</keyword>
	<keyword>recurrent and/or metastatic</keyword>
	<keyword>09-131</keyword>
</DOC>